NEW YORK (AP) — Drug developer Forest Laboratories Inc. said Friday its developing antibiotic ceftaroline met key study goals in treating hospital-acquired pneumonia. In two late-stage, or Phase III clinical trials, the drug had a higher cure rate than the antibiotic ceftriaxone in patients with moderate to severe forms of the condition. The company expects to ask for FDA approval near the end of the year.
